Monte Rosa Therapeutics, Inc.: capital expenditure payments
Capital expenditure payments for Monte Rosa Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Monte Rosa Therapeutics, Inc. financial histories
What this measure means
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
Exact concept: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 4,700,000 | USD | 2026-03-17 | 10-K · 0001193125-26-109360 |
| 2024-01-01 | 2024-12-31 | 3,988,000 | USD | 2026-03-17 | 10-K · 0001193125-26-109360 |
| 2023-01-01 | 2023-12-31 | 19,041,000 | USD | 2025-03-20 | 10-K · 0000950170-25-042344 |
| 2022-01-01 | 2022-12-31 | 12,911,000 | USD | 2024-03-14 | 10-K · 0000950170-24-031150 |
| 2021-01-01 | 2021-12-31 | 9,732,000 | USD | 2023-03-16 | 10-K · 0000950170-23-008440 |
| 2020-01-01 | 2020-12-31 | 3,389,000 | USD | 2022-03-29 | 10-K · 0000950170-22-004927 |
Related financial histories
- Monte Rosa Therapeutics, Inc.: total assets
- Monte Rosa Therapeutics, Inc.: total liabilities
- Monte Rosa Therapeutics, Inc.: stockholders equity
- Monte Rosa Therapeutics, Inc.: cash and cash equivalents
- Monte Rosa Therapeutics, Inc.: net income or loss
- Monte Rosa Therapeutics, Inc.: operating cash flow
- Monte Rosa Therapeutics, Inc.: financing cash flow
- Monte Rosa Therapeutics, Inc.: investing cash flow
- Monte Rosa Therapeutics, Inc.: retained earnings or deficit
- Monte Rosa Therapeutics, Inc.: basic weighted-average shares
- Monte Rosa Therapeutics, Inc.: diluted weighted-average shares
- Monte Rosa Therapeutics, Inc.: income tax expense or benefit
- Monte Rosa Therapeutics, Inc.: net property, plant and equipment
- Monte Rosa Therapeutics, Inc.: share-based compensation expense
- Monte Rosa Therapeutics, Inc.: operating income or loss
- Monte Rosa Therapeutics, Inc.: current assets
- Monte Rosa Therapeutics, Inc.: current liabilities
- Monte Rosa Therapeutics, Inc.: current accounts payable
- Monte Rosa Therapeutics, Inc.: operating expenses
- Monte Rosa Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Monte Rosa Therapeutics, Inc. / CIK 0001826457
- Captured
- 2026-09-21T17:29:10.378Z
- SEC response SHA-256
0a4a92fc3008d9e64736e7d0fd4da85bd1c7eaeca46286ae26b1364a7e47bbd8
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001826457.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))